University of Surrey

Test tubes in the lab Research in the ATI Dance Research

A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.

Nobes, JP, Langley, SE, Klopper, T, Russell-Jones, D and Laing, RW (2012) A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int, 109 (10). pp. 1495-1502.

Full text not available from this repository.

Abstract

Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Men with prostate cancer have higher rates of non-cancer mortality and CV morbidity and some of that excess risk has been attributed to the treatment they receive. ADT is an established treatment option for men with locally-advanced and metastatic prostate cancer and, although it has been shown to confer a disease-free survival advantage, it has also been associated with an increased incidence of CV disease and the metabolic syndrome (characterized by a cluster of CV risk factors, including insulin resistance). The benefits of the insulin sensitizer metformin and lifestyle intervention for reducing the incidence of metabolic syndrome have been shown in patients with impaired glucose tolerance. At the time of writing, the present study is the first to use metformin and lifestyle intervention in men with prostate cancer with the aim of reducing the risk of developing ADT-related CV morbidity and the metabolic syndrome. The study shows that lifestyle changes and metformin may indeed reduce the complications of androgen suppression in these men. Although further investigations are needed to establish which of the two interventions may be most beneficial, the favourable effects of a combination of these interventions on patients' quality of life and the potential for improved overall survival are of clinical significance.

Item Type: Article
Authors :
NameEmailORCID
Nobes, JPUNSPECIFIEDUNSPECIFIED
Langley, SEUNSPECIFIEDUNSPECIFIED
Klopper, TUNSPECIFIEDUNSPECIFIED
Russell-Jones, Ddavidrussell-jones@nhs.netUNSPECIFIED
Laing, RWUNSPECIFIEDUNSPECIFIED
Date : May 2012
Identification Number : 10.1111/j.1464-410X.2011.10555.x
Uncontrolled Keywords : Aged, Aged, 80 and over, Androgen Antagonists, Behavior Therapy, Blood Glucose, Disease-Free Survival, Follow-Up Studies, Great Britain, Humans, Hypoglycemic Agents, Insulin Resistance, Life Style, Male, Metabolic Syndrome X, Metformin, Middle Aged, Pilot Projects, Prospective Studies, Prostatic Neoplasms, Survival Rate, Treatment Outcome
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 09:35
Last Modified : 17 May 2017 09:35
URI: http://epubs.surrey.ac.uk/id/eprint/824336

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800